Immutep (ASX: IMM, NASDAQ: IMMP) continues to advance its immuno-oncology and autoimmune pipeline, with its lead candidate eftilagimod alpha (efti) showing encouraging results in clinical trials for ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has reported positive Phase 2 trial results for ATH434, its lead candidate for ...
Nico Resources (ASX: NC1) continues to advance its flagship Wingellina Nickel-Cobalt Project, a key asset in the Central ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback